SE459898B - Farmaceutisk, vattenhaltig, stabil komposition av ranitidin - Google Patents

Farmaceutisk, vattenhaltig, stabil komposition av ranitidin

Info

Publication number
SE459898B
SE459898B SE8402560A SE8402560A SE459898B SE 459898 B SE459898 B SE 459898B SE 8402560 A SE8402560 A SE 8402560A SE 8402560 A SE8402560 A SE 8402560A SE 459898 B SE459898 B SE 459898B
Authority
SE
Sweden
Prior art keywords
composition according
pharmaceutical composition
ranitidine
aqueous
value
Prior art date
Application number
SE8402560A
Other languages
English (en)
Swedish (sv)
Other versions
SE8402560L (sv
SE8402560D0 (sv
Inventor
J M Padfield
I K Winterborn
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10542680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE459898(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SE8402560D0 publication Critical patent/SE8402560D0/xx
Publication of SE8402560L publication Critical patent/SE8402560L/
Publication of SE459898B publication Critical patent/SE459898B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE8402560A 1983-05-13 1984-05-11 Farmaceutisk, vattenhaltig, stabil komposition av ranitidin SE459898B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838313217A GB8313217D0 (en) 1983-05-13 1983-05-13 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
SE8402560D0 SE8402560D0 (sv) 1984-05-11
SE8402560L SE8402560L (sv) 1984-11-14
SE459898B true SE459898B (sv) 1989-08-21

Family

ID=10542680

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8402560A SE459898B (sv) 1983-05-13 1984-05-11 Farmaceutisk, vattenhaltig, stabil komposition av ranitidin

Country Status (20)

Country Link
US (1) US4585790A (ja)
JP (1) JPH0639378B2 (ja)
AU (1) AU568647B2 (ja)
BE (1) BE899635A (ja)
CA (1) CA1216240A (ja)
CH (1) CH662272A5 (ja)
CZ (1) CZ281598B6 (ja)
DE (1) DE3417606C2 (ja)
DK (1) DK165663B (ja)
FR (1) FR2547727B1 (ja)
GB (2) GB8313217D0 (ja)
IE (1) IE57397B1 (ja)
IL (1) IL71813A (ja)
IT (1) IT1179367B (ja)
NL (1) NL194429C (ja)
NZ (1) NZ208127A (ja)
PH (1) PH20574A (ja)
SE (1) SE459898B (ja)
SK (1) SK279526B6 (ja)
ZA (1) ZA843584B (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
GB8927503D0 (en) * 1989-12-04 1990-02-07 Kronem Systems Inc Enzyme-amplified lanthanide chelate luminescence
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
WO1995010274A1 (en) * 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations
GB9715423D0 (en) 1997-07-23 1997-09-24 Glaxo Group Ltd Aqueous compositions
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
JP2004500378A (ja) * 2000-02-04 2004-01-08 ヨー、セオ、ホン 胆汁酸を含有する清浄水溶液製型の製造
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법
AU2002360025A1 (en) * 2001-12-27 2003-07-15 Terumo Kabushiki Kaisha Famotidine injection
JP2006008696A (ja) * 2003-03-20 2006-01-12 Mitsubishi Pharma Corp アルギニンアミド類を含有する医薬製剤
US7145125B2 (en) * 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8173627B2 (en) * 2004-08-30 2012-05-08 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
ATE506955T1 (de) * 2004-10-15 2011-05-15 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
AU2005302452B2 (en) * 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
JP2006271748A (ja) * 2005-03-30 2006-10-12 Taiyo Yakuhin Kogyo Kk 変質しない注射剤包装
WO2007022105A2 (en) * 2005-08-12 2007-02-22 Rubicon Research Pvt. Ltd. Stable pharmaceutical compositions, processes for making the same, and methods of their use
WO2008039792A1 (en) * 2006-09-25 2008-04-03 Scidose Llc Stable pharmaceutical compositions of preserved formulation of ranitidine, process for making the same, and methods of their use
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP3167876B1 (en) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CN113181110A (zh) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3626054A (en) * 1967-10-25 1971-12-07 Bard Hamilton Co Inc Lupus erythematosus skin test
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4203909A (en) * 1978-09-26 1980-05-20 Bristol-Myers Company Furan compounds
DE3108753A1 (de) * 1981-03-07 1982-09-16 Degussa Ag, 6000 Frankfurt Neue substituierte alkyl-phenylsulfonylguanidine miteinem heterocyclischen rest

Also Published As

Publication number Publication date
ZA843584B (en) 1985-12-24
GB8412108D0 (en) 1984-06-20
IT1179367B (it) 1987-09-16
FR2547727B1 (fr) 1988-02-26
SE8402560L (sv) 1984-11-14
DK165663B (da) 1993-01-04
DE3417606A1 (de) 1984-11-15
IE841179L (en) 1984-11-13
JPH0639378B2 (ja) 1994-05-25
GB2142820A (en) 1985-01-30
CA1216240A (en) 1987-01-06
CS403691A3 (en) 1992-08-12
GB2142820B (en) 1987-01-14
DK237884D0 (da) 1984-05-11
NL194429B (nl) 2001-12-03
AU2792984A (en) 1984-11-15
IE57397B1 (en) 1992-08-26
IL71813A0 (en) 1984-09-30
PH20574A (en) 1987-02-18
NZ208127A (en) 1987-05-29
AU568647B2 (en) 1988-01-07
SK279526B6 (sk) 1998-12-02
GB8313217D0 (en) 1983-06-22
NL194429C (nl) 2002-04-04
DE3417606C2 (de) 1996-03-14
IT8448182A0 (it) 1984-05-11
IL71813A (en) 1988-03-31
JPS59219225A (ja) 1984-12-10
BE899635A (fr) 1984-11-12
FR2547727A1 (fr) 1984-12-28
SE8402560D0 (sv) 1984-05-11
CZ281598B6 (cs) 1996-11-13
NL8401524A (nl) 1984-12-03
US4585790A (en) 1986-04-29
CH662272A5 (fr) 1987-09-30
DK237884A (da) 1984-11-14

Similar Documents

Publication Publication Date Title
SE459898B (sv) Farmaceutisk, vattenhaltig, stabil komposition av ranitidin
JP6886502B2 (ja) アトロピン含有水性組成物
US4690952A (en) Pharmaceutical compositions for nasal administration comprising calcitonin and an absorption-promoting substance
DK1044015T3 (da) Formuleringer med amylinagonistpeptider og insulin
JP2590156B2 (ja) 経口投与用医薬組成物
JP2024012211A (ja) ミカファンギン組成物
MXPA97002456A (en) Liquid antiacidal compositions containing calcium carbonate and possibly simeticone as active compounds and monobasic potassium phosphate and potassium bicarbonate as regula
RU2363462C2 (ru) Фармацевтическая композиция, содержащая 5-метил-2-(2′-хлор-6′-фторанилин)фенилуксусную кислоту
JP3146218B2 (ja) 点眼剤
US6818662B2 (en) Pharmaceutical composition
JPH07231926A (ja) 医薬水溶液を充填した軟質アンプル
AU2004281520B2 (en) Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
TR201510144A2 (tr) Yeni̇ oral çözelti̇ formülasyonu

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8402560-0

Format of ref document f/p: F

NUG Patent has lapsed